Compounded Cagrilintide and CagriSema: Legal Status and FDA Decision

As of October 19, 2026, no licensed pharmacy can lawfully compound cagrilintide or a "CagriSema" combination. Cagrilintide is not a component of any FDA-approved drug and is not on either federal bulks list, and FDA has said plainly that it "cannot be used in compounding under federal law." An FDA approval of CagriSema, which Novo Nordisk expects in the fourth quarter of 2026, would change one legal gate but would not create a cheaper compounded version.

Where CagriSema stands right now

CagriSema is a once-weekly injection that combines cagrilintide 2.4 mg, a long-acting amylin analog, with semaglutide 2.4 mg. Pharmaceutical Executive reported on December 18, 2025 that Novo Nordisk had filed a New Drug Application for chronic weight management in adults with obesity, or overweight with at least one weight-related condition.

The filing rests largely on the 68-week REDEFINE 1 trial in 3,417 adults without diabetes. In that trial, weight loss averaged 20.4% with CagriSema versus 3.0% with placebo, according to the same report. In a separate head-to-head trial, REDEFINE 4, CagriSema produced 23% weight loss at 84 weeks but did not meet its primary endpoint of non-inferiority to tirzepatide 15 mg, as summarized on Drugs.com's CagriSema approval history.

Novo's half-year financial report filed with the SEC on August 4, 2026 lists the CagriSema "US decision" as a Q4 2026 milestone. The Drugs.com tracker, with data updated through October 11, 2026, still lists the product as not FDA-approved.

Sources: Pharmaceutical Executive (Dec 18, 2025); Drugs.com CagriSema history; Novo Nordisk Form 6-K (Aug 4, 2026); FDA GLP-1 safety page (Oct 1, 2026).

Why a licensed pharmacy can't compound cagrilintide today

A state-licensed 503A pharmacy may compound from a bulk ingredient only if it passes one of three tests in 21 U.S.C. 353a(b)(1)(A)(i): it meets an applicable USP or National Formulary monograph; or, with no monograph, it is a component of an FDA-approved drug; or it appears on FDA's 503A bulks list. FDA's 503A bulk substances page adds that the ingredient must come from an FDA-registered manufacturer with a valid certificate of analysis.

FDA applied exactly this test to retatrutide, another investigational injectable, in a March 31, 2025 letter to the Federation of State Medical Boards. It found retatrutide was not the subject of a USP or NF monograph, "is not a component of an FDA-approved drug product," and did not appear on the 503A bulks list, so compounded versions "would not at this time qualify" under section 503A. FDA later sent state boards a similar letter about compounded cagrilintide, which the Alabama Board of Medical Examiners posted for its licensees.

FDA's own conclusion now appears on its GLP-1 safety page: "Retatrutide and cagrilintide cannot be used in compounding under federal law." The page explains that they are not components of FDA-approved drugs and have not been found safe and effective for any condition.

The outsourcing facility route is closed too

A 503B outsourcing facility may use a bulk ingredient only if it is on FDA's 503B "clinical need" list or the drug is on FDA's shortage list, under 21 U.S.C. 353b(a)(2)(A). Cagrilintide is on neither list on FDA's 503B bulks page, and there is no approved cagrilintide product that could be listed as in shortage.

What an FDA approval would change, and what it wouldn't

Approval would move cagrilintide into the second 503A category: a component of an approved drug. That removes the specific barrier FDA cites today. It does not open a general compounding market, for three reasons.

1. The "essentially a copy" rule would apply. FDA's April 1, 2026 compounding statement treats a compounded product as a copy when it has the same active ingredient, a similar strength, and the same route as a commercially available product. For products with two or more active ingredients, it applies the same strength and route tests to each. A compounded semaglutide-plus-cagrilintide injection at or near CagriSema's strengths would fit that description.
2. Copies are capped. The same statement says FDA does not intend to act against a 503A pharmacy that fills "four or fewer prescriptions of that compounded drug product during a calendar month." Above that, copies made "regularly or in inordinate amounts" are outside the exemption.
3. 503B still needs a list or a shortage. Approval alone does not put cagrilintide on the 503B bulks list. Outsourcing facilities would remain shut out unless FDA added it or listed CagriSema as in shortage.

The exception for a prescriber-documented clinical difference would still exist. FDA's 2018 essentially-a-copy guidance requires the prescription to state the specific change and the significant difference it makes for that patient. A note with only a patient name and formulation is not enough.

One open question: how FDA would treat a cagrilintide-only preparation if only the combination is approved. FDA has not publicly addressed that scenario, so any seller claiming it is settled law is getting ahead of the agency.

Source: 21 U.S.C. 353a and 353b; FDA April 1, 2026 statement; FDA 2018 guidance; FDA GLP-1 safety page (Oct 1, 2026). This table describes federal rules only; state law can be stricter.

How to spot research-peptide sellers

Cagrilintide is already marketed online. In a March 31, 2026 warning letter, FDA told one peptide seller that its cagrilintide, along with products it identified as retatrutide, semaglutide, tirzepatide, and mazdutide, were unapproved new drugs. FDA said that despite "laboratory research purposes only" labeling, evidence from the seller's website established the products were intended for human use. The letter also treated "BAC water" sold in a kit with a syringe as a drug.

FDA's safety page warns that products "falsely labeled 'for research purposes'" have been sold to consumers with dosing instructions and are "of unknown quality." Common signs:

1. "Research use only" or "not for human consumption" next to dosing charts, weight-loss claims, or reconstitution instructions.
2. Kits that bundle vials, bacteriostatic water, and syringes.
3. Names like "CagriSema," "cagri-sema blend," or "GLP-1 + amylin stack" on a product with no prescription requirement.
4. No pharmacy name, license number, or prescriber anywhere in the process.
5. Claims that a product is "the same as" Novo's investigational drug. There is no approved CagriSema to be the same as.

Worked example

Suppose a website advertises "compounded cagrilintide/semaglutide, made by a licensed 503A pharmacy," in October 2026. Run the checks. Cagrilintide has no lawful 503A pathway today, according to FDA. The semaglutide component faces its own essentially-a-copy limits because Wegovy and Ozempic are commercially available. The claim of 503A status does not change the ingredient problem. On FDA's stated position, the product cannot be a lawful compounded drug, whatever the label says about the pharmacy.

Scenario guidance

• A telehealth service offers "CagriSema" now. Ask for the dispensing pharmacy, its license number, and the cagrilintide source. Given FDA's statement, the honest answer cannot be a lawful compounded product.
• You are waiting for approval. Talk with your prescriber about approved options in the meantime. Approval, if it comes, would make Novo's product available by prescription; it would not make a compounded version routine.
• You already have "research" cagrilintide. Do not use it while you get advice. Keep the packaging and lot information.

Questions to ask your pharmacy or prescriber

1. Is this an FDA-approved product, a compounded product, or something else?
2. If compounded, under 503A or 503B, and which ingredient source and registered manufacturer?
3. Given FDA's statement that cagrilintide cannot be used in compounding, what legal basis do you rely on?
4. Can I see the certificate of analysis and the pharmacy's state license?
5. If CagriSema is approved, what will you prescribe, and how will cost and coverage work?

Where this guide stops

This guide reflects federal FDA rules and public company filings through October 19, 2026. It does not predict whether or when FDA will approve CagriSema, what its label will say, or how FDA would apply its copy policy to a cagrilintide-only product. It does not cover patent rights, state pharmacy law, or any specific seller. Recheck FDA's records before acting on anything here.

Compare available care options

If you are choosing a provider for an FDA-approved GLP-1 while CagriSema's review continues, compare what each will confirm in writing: prescriber license, dispensing pharmacy, and full cost. A listing is not a recommendation or a prescription; verify credentials and terms yourself.

Affiliate disclosure: this site may earn a commission if you use a listed provider. Compensation does not establish a provider's safety, legality, or value.

Sources

1. Pharmaceutical Executive: Novo Nordisk submits NDA to FDA for CagriSema (December 18, 2025)
2. Drugs.com: CagriSema FDA approval status and history (data through October 11, 2026)
3. Novo Nordisk Form 6-K, financial report for January–June 2026 (August 4, 2026)
4. FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026)
5. 21 U.S.C. 353a, Pharmacy compounding (section 503A)
6. 21 U.S.C. 353b, Outsourcing facilities (section 503B)
7. FDA: Bulk drug substances used in compounding under section 503A
8. FDA: Bulk drug substances used in compounding under section 503B
9. FDA letter to the Federation of State Medical Boards on compounded retatrutide (March 31, 2025)
10. Alabama Board of Medical Examiners: FDA letter on compounded drug products containing cagrilintide
11. FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 1, 2026)
12. FDA guidance: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (January 2018)
13. FDA Warning Letter 721805 to a peptide seller (March 31, 2026)

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.